Search research articles
Contact Us
Filters
Showing results (191-200 of 209) with videos related to
Page
of 21
Sort By:
American Journal of Ophthalmology
|
July 13, 2016
Reply
Hans Hoerauf, Nicolas Feltgen, Claudia Weiss, et al.
International Journal of Toxicology
|
June 10, 2011
Investigation of correlation among safety biomarkers in serum, histopathological examination, and toxicogenomics
Tao Wang, Maria Papoutsi, Marion Wiesmann, et al.
American Journal of Ophthalmology
|
May 11, 2016
Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study
Hans Hoerauf, Nicolas Feltgen, Claudia Weiss, et al.
Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft
|
May 16, 2019
[Development and validation of novel clinical endpoints in intermediate age-related macular degeneration in MACUSTAR]
Jan H Terheyden, Robert P Finger, Steffen Schmitz-Valckenberg, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
October 24, 2014
Phase II metabolism in human skin: skin explants show full coverage for glucuronidation, sulfation, N-acetylation, catechol methylation, and glutathione conjugation
Nenad Manevski, Piet Swart, Kamal Kumar Balavenkatraman, et al.
Leukemia Research
|
February 4, 2010
Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies
Armin Wolf, Philippe Couttet, Min Dong, et al.
Alternatives to Laboratory Animals : ATLA
|
July 13, 2006
The assessment of repeated dose toxicity in vitro: a proposed approach. The report and recommendations of ECVAM workshop 56
Pilar Prieto, Alan W Baird, Bas J Blaauboer, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
February 13, 2018
Bile Acid Sequestration by Cholestyramine Mitigates FGFR4 Inhibition-Induced ALT Elevation
Heiko S Schadt, Armin Wolf, Joerg Andreas Mahl, et al.
Molecular Cancer Therapeutics
|
August 15, 2019
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Andreas Weiss, Flavia Adler, Alexandra Buhles, et al.
The British Journal of Ophthalmology
|
August 7, 2019
Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study
Richard P Gale, Ian Pearce, Nicole Eter, et al.
Page
of 21
Search research articles
Search
Showing results (191-200 of 209) with videos related to
Sort By:
Page
of 21
American Journal of Ophthalmology
|
July 13, 2016
Reply
Hans Hoerauf, Nicolas Feltgen, Claudia Weiss, et al.
International Journal of Toxicology
|
June 10, 2011
Investigation of correlation among safety biomarkers in serum, histopathological examination, and toxicogenomics
Tao Wang, Maria Papoutsi, Marion Wiesmann, et al.
American Journal of Ophthalmology
|
May 11, 2016
Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study
Hans Hoerauf, Nicolas Feltgen, Claudia Weiss, et al.
Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft
|
May 16, 2019
[Development and validation of novel clinical endpoints in intermediate age-related macular degeneration in MACUSTAR]
Jan H Terheyden, Robert P Finger, Steffen Schmitz-Valckenberg, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
October 24, 2014
Phase II metabolism in human skin: skin explants show full coverage for glucuronidation, sulfation, N-acetylation, catechol methylation, and glutathione conjugation
Nenad Manevski, Piet Swart, Kamal Kumar Balavenkatraman, et al.
Leukemia Research
|
February 4, 2010
Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies
Armin Wolf, Philippe Couttet, Min Dong, et al.
Alternatives to Laboratory Animals : ATLA
|
July 13, 2006
The assessment of repeated dose toxicity in vitro: a proposed approach. The report and recommendations of ECVAM workshop 56
Pilar Prieto, Alan W Baird, Bas J Blaauboer, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
February 13, 2018
Bile Acid Sequestration by Cholestyramine Mitigates FGFR4 Inhibition-Induced ALT Elevation
Heiko S Schadt, Armin Wolf, Joerg Andreas Mahl, et al.
Molecular Cancer Therapeutics
|
August 15, 2019
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Andreas Weiss, Flavia Adler, Alexandra Buhles, et al.
The British Journal of Ophthalmology
|
August 7, 2019
Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study
Richard P Gale, Ian Pearce, Nicole Eter, et al.
Page
of 21